top of page
Lab Experiments


Below are a list of key discoveries that stem from our published mouse model study and patent claims.


  • The compound helps to moderate the cytokine storm which stops the immune system going crazy and harming the cells of the body, like what happens in auto-immune diseases.

  • Moderates free radical damage by helping to prevent asbestos fibre damage to lung cells.

  • Macrophages capture and remove asbestos fibres from tissues and organs, like little garbage trucks driving around picking up the asbestos fibres and taking them out of the body. In asbestos treated mice, the tissues have very low macrophage populations but with the compound (plus asbestos) macrophage numbers return to near normal.

  • First compound to show promising results for a disease that responds poorly to current cancer treatments.

  • The compound has the potential to be used for treating patients with asbestos related diseases (asbestosis and mesothelioma) and as a preventative for people who have be exposed to asbestos that have not yet shown symptoms of the diseases.

  • The compound may be used in different delivery modes, that is, by direct intubation or injection at the site of tumours, or by respiratory nebulisers and puffers.


Bio-latem Technologies Pty Limited Timeline for bringing the IP/invention to commercialisation status


Next steps to bring project to commercialisation 

Toxicology Testing:

We need to commission an external company (Charles River Laboratories) for animal toxicology testing, which is an Australian TGA prerequisite for setting up and performing pilot trials in humans.



We are currently exploring two avenues of early diagnosis using biomarkers.  If successful, these will be effective early predictors of a predisposition to MM or asbestosis and treatments may stave off or prevent the progression of the disease.


Mouse lung trials:

We have a research team ready to implement a full mouse lung trial study to confirm our earlier mouse trial study which will parallel the best possible comparison with human lung trials.  If the success of the lung trial is as good as our peritoneal mouse trail, then a Phase I human clinical trial will be fast tracked.

The project to date has received support from a number of sources, however this has been sporadic. Before we undertake the next phase of the project we need to find a reliable source of funding.  We are simply two individuals passionate about driving this project to completion and kindly ask for any funding support.



The above graphic illustrates three areas of our IP that can be commercially developed and how they relate to one another, outlining a comprehensive diagnostic/treatment model. 

bottom of page